NASDAQ:KYMR.O 2 January 2026

Kymera shares fell 6.9% to $72.42 Friday after a regulatory filing showed CEO Nello Mainolfi sold 30,000 shares for about $2.34 million at year-end under a pre-set trading plan. The drop outpaced the broader biotech sector. Investors are watching for KT-621 asthma trial milestones in early 2026.